Nephrol Dial Transplant (2001) 16: 1631-1637
© 2001 European Renal Association-European Dialysis and Transplant Association
ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis
Fifth Medical Clinic (Nephrology, Endocrinology), University-Clinic Mannheim, Faculty of Clinical Medicine of the University of Heidelberg, Mannheim, Germany
Background. Antineutrophil cytoplasmic autoantibodies (ANCA) are presumed to reflect disease-activity and to be useful for guidance of immunosuppressive therapy of ANCA-associated systemic vasculitis (AASV), but with respect to conventional ANCA assays this is controversial. ANCA titres, measured in the IgG3 subclass and modern capture ELISAs, have been said to be superior predictors of relapses of AASV.
Methods. In this retrospective study serial measurements of ANCA parameters and soluble CD14 (sCD14) were performed in 169 consecutive sera over a median of 21 months in 18 patients with AASV and related to disease activity, assessed by Birmingham Vasculitis Activity Score (BVAS) for new or deteriorated (BVAS1), and for chronic disease activity (BVAS2). Fourteen patients had Wegener's granulomatosis (WG) and were C-ANCA positive with Pr 3-antibodies and four patients had microscopic polyangiitis (MPA) with P-ANCA and MPO-antibodies. In WG patients ANCA by IIF, Pr 3-ELISA for IgG, IgG1, IgG3, IgG4 and sCD14 were measured, as well as capture ELISA for Pr 3, and in MPA patients ANCA by IIF, MPO-ELISA for IgG and IgG1, IgG3, IgG4, and sCD14 respectively. In eight patients, data collection started at diagnosis, in 10 patients at remission.
Results. The parameters predicted neither the nine major relapses (increase of immunosuppression necessary), nor the 26 minor relapses (increase of BVAS1>2) with sufficient sensitivity (>80%) or specificity (> 90%90%), and they also failed to predict relapses within the following 2 months. ANCA-IgG3 and capture ELISA for Pr 3 were not advantageous for prediction of relapses (sensitivity 0.45 and 0.19 respectively), and sCD14 remained elevated in all samples irrespective of disease activity.
Conclusions. There is no rationale for serial measurements of ANCA in AASV. For changes of therapy, the ANCA parameters should only be used in conjunction with clinical information.
Keywords: IgG subclasses; prognostic value of ANCA; relapses; soluble CD14; systemic vasculitis
Correspondence and offprint requests to: Dr Rainer Nowack, Inselgraben 6, D-88131 Lindau, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. D. Finkielman, P. A. Merkel, D. Schroeder, G. S. Hoffman, R. Spiera, E. W. St. Clair, J. C. Davis Jr., W. J. McCune, A. K. Lears, S. R. Ytterberg, et al. Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med, November 6, 2007; 147(9): 611 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Colman, A. Hussain, M. Goodall, S. P Young, T. Pankhurst, X. Lu, R. Jefferis, C. O S Savage, and J. M Williams Chimeric antibodies to proteinase 3 of IgG1 and IgG3 subclasses induce different magnitudes of functional responses in neutrophils Ann Rheum Dis, May 1, 2007; 66(5): 676 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kallenberg, C. Stegeman, H Bootsma, M Bijl, and P. Limburg Quantitation of Autoantibodies in Systemic Autoimmune Diseases: Clinically Useful? Lupus, July 1, 2006; 15(7): 397 - 402. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Hewins, J. M. Williams, M. J.O. Wakelam, and C. O.S. Savage Activation of Syk in Neutrophils by Antineutrophil Cytoplasm Antibodies Occurs via Fc{gamma} Receptors and CD18 J. Am. Soc. Nephrol., March 1, 2004; 15(3): 796 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Little, L. Nazar, and K. Farrington Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity Nephrol. Dial. Transplant., February 1, 2004; 19(2): 356 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Segelmark, B. D. Phillips, S. L. Hogan, R. J. Falk, and J. C. Jennette Monitoring Proteinase 3 Antineutrophil Cytoplasmic Antibodies for Detection of Relapses in Small Vessel Vasculitis Clin. Vaccine Immunol., September 1, 2003; 10(5): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Stegeman Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2077 - 2080. [Full Text] [PDF]
|
|
|
|
|
|
F. J. van der Woude Taking anti-neutrophil cytoplasmic antibody (ANCA) testing beyond the limits Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2081 - 2083. [Full Text] [PDF]
|
|